Similar articles

• Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.

  [No authors listed] [No authors listed] AIDS Patient Care STDS. 2007 Aug;21(8):6-3. AIDS Patient Care STDS. 2007. PMID: 17902242 No abstract available.
• A lame duck, a dark horse, and a goat.

  Huff B. Huff B. GMHC Treat Issues. 2005 May-Jun;19(5-6):4-5. GMHC Treat Issues. 2005. PMID: 16193576 No abstract available.
• Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.

  Berhan A, Berhan Y. Berhan A, et al. PLoS One. 2013 Apr 4;8(4):e60814. doi: 10.1371/journal.pone.0060814. Print 2013. PLoS One. 2013. PMID: 23593314 Free PMC article.
• Protease inhibitors: the current status.

  Dauer B. Dauer B. J HIV Ther. 2005 Dec;10(4):72-4. J HIV Ther. 2005. PMID: 16519246 Review. No abstract available.
• New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.

  Lascar M, Cartledge JD. Lascar M, et al. J HIV Ther. 2008 Jun;13(2):40-4. J HIV Ther. 2008. PMID: 18953273 Review. No abstract available.